Sixty-five percent of the deaths are related to cardiovascular causes.

Rosiglitazone may increase risk of death from cardiovascular causes though the causal connection is unclear.

Since the study, involving 4,447 people, began nearly four years ago, 29 patients in the Avandia group have died from cardiovascular causes.

The combined primary end point was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke.

If death occurs, it is usually due to either respiratory (typically asphyxia) or cardiovascular causes (shock), with 0.7-20% of cases causing death.

If death occurs, it is usually due to either a respiratory cause (typically closing off of the airway) or a cardiovascular cause (shock).

Among participants hospitalized for HF who subsequently died, over half of the deaths in each drug group were attributed to cardiovascular causes.

In fact, at least 65% of people with diabetes die from some cardiovascular cause, according to the AHA.

The number of deaths from cardiovascular causes among the two groups was nearly the same, 81 for those who took aspirin, 83 for those who did not.